Literature DB >> 10711706

Functional characterization of organic cation drug transport in the pigmented rabbit conjunctiva.

H Ueda1, Y Horibe, K J Kim, V H Lee.   

Abstract

PURPOSE: To characterize carrier-mediated organic cation drug transport in the rabbit conjunctiva.
METHODS: The transport of [14C]guanidine, the model substrate, in the excised pigmented rabbit conjunctiva was evaluated in the modified Ussing chamber. Tetraethylammonium (TEA) transport also was investigated to determine substrate specificity.
RESULTS: The apparent permeability coefficient for guanidine and TEA in the mucosal-to-serosal (ms) direction was 5.4 and 49.6 times greater than that in the serosal-to-mucosal (sm) direction, respectively. Guanidine transport in the ms (but not sm) direction revealed temperature and concentration dependency over 0.02 to 10 mM with an apparent Michaelis-Menten constant of 3.1 mM and a maximal flux of 11.4 nmol/(cm2 x h). Net guanidine transport measured at 0.1 mM across the conjunctiva was decreased by 71% or 82%, respectively, on the addition of 1 microM valinomycin (a K+ ionophore) in both bathing fluids or in a high K+ buffer in the mucosal fluid. Interestingly, net guanidine transport was reduced, rather than enhanced, by 63% upon acidifying the mucosal bathing fluid. By contrast, net guanidine transport was not affected by the serosal presence of 0.5 mM ouabain (a Na+, K+-ATPase inhibitor), by the mucosal and serosal presence of 0.1 microM monensin (a Na+ ionophore) or 0.3 microM carbonyl cyanide p-(trifluoromethoxy)phenyl-hydrazone (FCCP, a H+ ionophore). Guanidine transport in the ms direction was polyspecific, as indicated by the 48% to 82% inhibition by structurally diverse amines. In particular, guanidine ms transport was inhibited by the antiglaucoma drugs dipivefrine (72%), brimonidine (70%), and carbachol (78%).
CONCLUSIONS: A carrier-mediated organic cation transport process appears to exist in the conjunctiva, mediating the absorption of organic amines, including certain amine-type ophthalmic drugs. This process may be driven by an inside-negative apical membrane potential difference.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10711706

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Neutrophils compromise retinal pigment epithelial barrier integrity.

Authors:  Jiehao Zhou; Shikun He; Ning Zhang; Christine Spee; Peng Zhou; Stephen J Ryan; Ram Kannan; David R Hinton
Journal:  J Biomed Biotechnol       Date:  2010-03-03

2.  Immunohistochemical and functional characterization of peptide, organic cation, neutral and basic amino acid, and monocarboxylate drug transporters in human ocular tissues.

Authors:  Rajendra S Kadam; Sunil K Vooturi; Uday B Kompella
Journal:  Drug Metab Dispos       Date:  2012-11-20       Impact factor: 3.922

3.  Role of P-glycoprotein in restricting propranolol transport in cultured rabbit conjunctival epithelial cell layers.

Authors:  J J Yang; K J Kim; V H Lee
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

Review 4.  Recent advances in ophthalmic drug delivery.

Authors:  Uday B Kompella; Rajendra S Kadam; Vincent H L Lee
Journal:  Ther Deliv       Date:  2010-09

5.  Effect of brimonidine, an α2 adrenergic agonist, on human meibomian gland epithelial cells.

Authors:  Xi Han; Yang Liu; Wendy R Kam; David A Sullivan
Journal:  Exp Eye Res       Date:  2018-02-13       Impact factor: 3.467

6.  Potential pharmacokinetic role of organic cation transporters in modulating the transcorneal penetration of its substrates administered topically.

Authors:  J Nirmal; S B Singh; N R Biswas; V Thavaraj; R V Azad; T Velpandian
Journal:  Eye (Lond)       Date:  2013-07-12       Impact factor: 3.775

7.  Transport of L-carnitine in human corneal and conjunctival epithelial cells.

Authors:  Shunjiang Xu; Judith L Flanagan; Peter A Simmons; Joseph Vehige; Mark D Willcox; Qian Garrett
Journal:  Mol Vis       Date:  2010-09-04       Impact factor: 2.367

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.